Schweikert Keeps Taking Checks From Big Pharma Corporations Who Are Suing to End Medicare’s Ability to Negotiate Lower Drug Prices

Schwiekert Voted Against Medicare Negotiation In 2022

PHOENIX — Federal Election Commission filings were due yesterday, and Congressman David Schweikert's report showed that he's still taking campaign contributions from groups that are suing to end Medicare’s ability to negotiate lower prescription drug prices – a highly popular provision of the Inflation Reduction Act that Congressman Schweikert voted against.

Thanks to the passage of the Inflation Reduction Act, Medicare has the power to negotiate the cost of some of the most expensive and heavily prescribed drugs for Medicare patients. According to the Kaiser Family Foundation, 83 percent of Americans favor Medicare’s ability to negotiate drug prices.

Novo Nordisk donated to Congressman Schweikert's reelection bid – the sum accounts for a third of all the contributions from Novo Nordisk to Congressman Schweikert this cycle. Novo Nordisk brought a lawsuit to overturn the Inflation Reduction Act’s provision to allow Medicare to negotiate lower drug prices.  During the current election cycle, Congressman Schweikert already received checks from Johnson & Johnson, Novartis and the lobbying group PhRMA, all of which were party to  lawsuits to overturn Medicare price negotiation.

“Congressman Schweikert has shown through his votes and the donations he accepts that he's on the side of Big Pharma and not the Arizonans he's supposed to represent,” said Les Braswell with Honest Arizona. “Congressman Schweikert needs to stop working to undermine Medicare negotiation and side with his constituents by supporting lower drug costs.”

###